PHARMAC proposal open for feedback
The medicines are:
· Infliximab (Remicade)
· Rituximab (Mabthera)
· Tocilizumab (Actemra)
Rituximab (Mabthera) is already funded in Section B of the Pharmaceutical Schedule for its use in blood cancers. This change would result in the current Special Authority criteria being extended to include its other current hospital uses, including rheumatoid arthritis, haemophilia with inhibitors and steroidresistant nephrotic syndrome. Infliximab (Remicade) and tocilizumab (Actemra) would be listed in Section B of the Pharmaceutical Schedule subject to Special Authority restrictions that match the current Section H restrictions applying to their use.
This proposal is open to feedback until 5pm on Friday 5 October 2018.
If you wish to provide feedback: email@example.com
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.